Comparison
BPC-157 vs TB-500
BPC-157 and TB-500 are the two most studied recovery peptides and act through complementary mechanisms: BPC-157 drives angiogenesis via VEGF and nitric oxide pathways, while TB-500 promotes cell migration via G-actin sequestration and ILK signalling.
BPC-157 and TB-500 are the two most extensively studied recovery peptides in the research literature, and they act through distinct but complementary mechanisms that explain why researchers frequently study them together. BPC-157 (body protection compound 157) is a 15-amino-acid pentadecapeptide with a molecular weight of 1,419.5 Da and a half-life of approximately 4 hours. TB-500 is a synthetic analog of Thymosin Beta-4, a 43-amino-acid protein with a molecular weight of 4,963.5 Da and a half-life of roughly 3 to 4 hours.
How do BPC-157 and TB-500 differ in mechanism?
BPC-157 acts primarily through angiogenesis. Studies report that it upregulates vascular endothelial growth factor (VEGF-A) and its receptor VEGFR-2 to drive new capillary formation into damaged tissue, and it activates the FAK-paxillin pathway to promote fibroblast and tenocyte migration (Sikiric et al., 2018, PMID: 29210636). TB-500 acts through actin dynamics: research shows Thymosin Beta-4 sequesters G-actin monomers to maintain a mobile actin pool for cytoskeletal remodeling and activates integrin-linked kinase (ILK), which signals through Akt and ERK1/2 to promote cell migration and survival (Goldstein & Kleinman, 2015, PMID: 25917514).
What does research show about each peptide?
BPC-157 has the strongest preclinical evidence base for tendon-to-bone healing, ligament repair, and gastrointestinal mucosal protection, with over 300 published preclinical studies. TB-500 has comparatively stronger documented evidence for cardiac repair — Bock-Marquette et al. (2004) reported reduced infarct size and improved cardiac function in murine myocardial infarction models — and for skeletal muscle satellite cell activation.
| Metric | BPC-157 | TB-500 |
|---|---|---|
| Class | Pentadecapeptide (gastric BPC-derived) | Thymosin Beta-4 synthetic analog |
| Sequence length | 15 amino acids | 43 amino acids |
| Molecular weight | 1,419.5 Da | 4,963.5 Da |
| Half-life | ~4 hours | ~3–4 hours |
| Primary mechanism | VEGF-driven angiogenesis; FAK-paxillin migration | G-actin sequestration; ILK-Akt-ERK migration |
| Strongest evidence | Tendon/ligament, GI mucosa | Cardiac repair, muscle satellite cells |
| Key reference | PMID: 29210636 | PMID: 25917514 |
The two are complementary rather than interchangeable: BPC-157 targets the vascular and fibroblast response, TB-500 targets the cytoskeletal migration response. Read the BPC-157 monograph and the TB-500 monograph for full citation summaries.
Research Use Only · Not for human consumption · Not for veterinary use.